Biotech entity

Josh Hawley

Person

Every one of those 1 sits in a single category, pharma. Catherine Hanaway is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Each carries 2 original sources on average. We currently track 1 Biotech story that mention Josh Hawley, all published on March 13, 2026.

Last mentioned: Mar 13, 2026

Entity pulse

Recent coverage · Josh Hawley

1 story
8 avg impact
0% positive
100% negative

Coverage balance Negative coverage leads. Negative coverage exceeds positive coverage by 100 percentage points.

  • 100% negative

Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.

What the coverage shows about Josh Hawley

Every one of those 1 sits in a single category, pharma. Catherine Hanaway is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Each carries 2 original sources on average. We currently track 1 Biotech story that mention Josh Hawley, all published on March 13, 2026.

Stories tracked
1
Sources per story
2

Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 18 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.

Coverage cohort

Appears alongside

Other entities that clear the same relevance threshold in stories also covering Josh Hawley. Shared-story counts are live from our verified record — not editorial picks.

Timeline

  1. Missouri Pause Request

    DOJ files a request in federal court to pause the Missouri-led lawsuit citing an ongoing FDA review.

  2. Hawley Federal Bill

    Senator Josh Hawley introduces a bill in the Senate to ban mifepristone nationwide.

  3. Louisiana Pause Request

    DOJ asks Louisiana to pause its separate lawsuit; request is rejected by AG Liz Murrill.

  4. Missouri Lawsuit Filed

    Missouri, Kansas, and Idaho file suit against the FDA to restrict mifepristone access.

Stories mentioning Josh Hawley 1

Pharma Negative

DOJ Seeks Pause in Missouri Mifepristone Suit Amid FDA Review Strategy

The Department of Justice has requested a federal court to pause a multi-state lawsuit against the FDA regarding the abortion pill mifepristone. The move suggests a strategic effort to allow the FDA to conduct its own internal review of the drug's safety and distribution protocols.

2 sources

Josh Hawley is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.

See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.